Using buspirone to help treat opioid withdrawal symptoms
Evaluating a Mechanistically-Supported Pharmacotherapy to Treat Acute and Protracted Opioid Withdrawal
This study is looking at how well the medication buspirone can help people with opioid use disorder feel better during and after they reduce their use of morphine, and if you join, you'll help us learn more about how it can make treatment easier for others.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10878779 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of buspirone, a medication that may help alleviate both acute and protracted withdrawal symptoms in individuals with opioid use disorder (OUD). Participants will undergo a structured treatment plan that includes a morphine tapering process, followed by outpatient support where their symptoms and cravings will be closely monitored. The study aims to provide a thorough evaluation of buspirone's safety and efficacy as an adjunct therapy during and after the tapering process. By participating, individuals will contribute to understanding how this medication can improve treatment outcomes for those struggling with opioid dependence.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are undergoing or have recently undergone opioid tapering.
Not a fit: Patients who are not experiencing opioid withdrawal or those who are not diagnosed with opioid use disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for individuals experiencing opioid withdrawal, potentially reducing relapse rates.
How similar studies have performed: Previous studies have shown promising results for buspirone in treating withdrawal symptoms, indicating a potential for success in this approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Bergeria, Cecilia — Johns Hopkins University
- Study coordinator: Bergeria, Cecilia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.